KAZANCHYAN ANNA 4
4 · Foamix Pharmaceuticals Ltd. · Filed May 20, 2019
Insider Transaction Report
Form 4
KAZANCHYAN ANNA
Director
Transactions
- Sale
Ordinary Shares
2019-05-20$2.61/sh−10,600$27,666→ 45,355 total - Award
Ordinary Shares
2019-05-16+28,195→ 55,955 total
Footnotes (4)
- [F1]This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- [F2]The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020.
- [F3]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2019.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.57 to $2.68 inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.